LabLaunch
A grants, partnerships, and cluster-intel dashboard that gives early-stage UK biotech founders a single window into funding, talent, and collaboration signals across the Cambridge 'Golden Triangle'.
Early-stage UK biotech founders scouting Cambridge and the wider Golden Triangle life sciences ecosystem
- Curated feed of UK biotech grants (Innovate UK, NIHR, Life Sciences Catalyst) auto-matched to your modality and stage
- Cluster intel feed: which companies are hiring, partnering, IPO-ing, or relocating R&D between Stevenage, Cambridge, Oxford, and London
- Saved-search alerts that fire when a relevant call opens or a peer raises a round in your therapeutic area
- Plain-English briefs of newly published academic papers with industry-relevance tags for founders without a science team on staff
GSK is consolidating 1,000 R&D staff from Stevenage into Cambridge, accelerating the gravitational pull of the Golden Triangle; founders need a focused way to track funding, talent, and partnership signals in that cluster.
Cambridge cluster raised ~$1.3–2.3B in 2024 and GSK confirmed ~1,000 R&D staff relocating to Cambridge by 2029, but the narrow buyer — pre-Series-A biotech founders — is a small subset of that activity.Pharma giant GSK quits Stevenage for Cambridge ↗Cambridge VC investment surges to $2.3 billion as science-led innovation abounds ↗
No direct Golden-Triangle-focused founder dashboard surfaced; closest substitutes are investor-oriented (Beauhurst, Dealroom) or generic grant lists (Get Grants, UKStartups) and university portals (Cambridge Enterprise).Beauhurst: The Ultimate Private Company Data Source ↗Grants - Cambridge Enterprise ↗
Beauhurst and Dealroom both market premium/enterprise tiers to investors and corporates, indicating willingness to pay at the institutional level — but the stated target user (pre-revenue early-stage founders) typically has near-zero software budget, and no public pricing for a founder-tier product exists.Pricing - Beauhurst ↗Pricing | Dealroom.co ↗
Cambridge has been named the world's most intense S&T cluster by Global Innovation Index three years running, anchored by the University of Cambridge, AstraZeneca, and the now-confirmed GSK relocation through 2029 — structural, multi-decade drivers.A State-of-the-Art Science & Innovation Campus ↗UK biotech financing 2024 - Cambridge Innovation Capital ↗
Underlying data sources (Companies House, Innovate UK grants, BIA reports, labiotech/endpoint news feeds) are largely public, but clustering partnership/talent signals and keeping them curated for a specific geography is non-trivial and ongoing work.Cambridge's biotech hub: The heart of the UK's Golden Triangle ↗Funding Database - UK Small Business Startups and Funding ↗